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www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMp ¼ 0.009). At 1-year, mortality rate was higher in group II (6.1% vs. 26.3%; hazard
ratio [HR], 4.46; 95% CI, 1.34 – 14.83: p ¼ 0.029). Multivariate Cox regression
analysis identiﬁed preoperative mitral regurgitation  moderate (HR, 5.35; 95% CI,
1.58 – 18.10; p ¼ 0.007) and body mass index (HR, 0.75; 95% CI, 0.60 – 0.94;
p ¼ 0.012) as independent predictors of mortality.
Conclusions: Preoperative mitral regurgitation  moderate was associated with
higher 30-day and 1-year mortality.TCT-726
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Background: Pulmonary hypertension (PHTN) is a major risk factor for patients
undergoing cardiac surgery as it associated with high peri- and post-operative mor-
tality. There is limited data on PHTN among patients who undergo transcatheter aortic
valve replacement (TAVR). This analysis sought to assess the prevalence and clinical
impact of PHTN of such patients.
Methods: Clinical data of patients with AS who underwent TAVR was retrospec-
tively analyzed. Patients were divided into two groups based on systolic pulmonary
artery pressure: 0-50 mmHg (No/Mild group) versus >50 mmHg (moderate/severe
group).
Results: A total of 415 patients were included. No/mild PHTN was present in 172
(41.5%) and moderate/severe PHTN in 243 (58.5%). The average age was 848 years
and 47% were male. Average STS score was 10.04.7. There were no signiﬁcant
differences between groups in baseline characteristics or in baseline echo, apart from
moderate/severe tricuspid regurgitation, which was more frequent among moderate/
severe PHTN patients (23% vs. 5.9%, p < 0.001) and average baseline pulmonary
pressure (6112 vs. 379, p < 0.001). Procedural and post-procedural complications
were similar. (Figure) Mortality at 30 days and 1-year follow up was signiﬁcantly
higher in the moderate/severe PHTN group (30 days 14.5% vs. 7.4%, p¼0.019, and 1
year 30.8% vs. 21.0%, p¼0.023).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaConclusions: Patients with severe aortic stenosis and pulmonary hypertension, un-
dergoing TAVR may have some improvement in their PHTN and tricuspid regurgi-
tation indices. Nevertheless, this group has higher mortality rate and should subjected
ti intense monitoring and treatment
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Background: The repositionable and fully retrievable, CE-marked Lotus Valve is
designed to facilitate controlled, precise positioning and minimize paravalvular aortic
regurgitation. Results to 2 years post-implantation with Lotus have not yet been
reported.
Methods: REPRISE I is a prospective, single-arm, 3-center feasibility study designed
to assess acute safety and performance of the 23mm Lotus Valve in symptomatic
patients with calciﬁed aortic stenosis and high surgical risk.
Results: The Lotus Valve was implanted in 11 female patients (mean age 83.03.6
years; mean STS score 4.92.5%). All patients were considered high risk for surgery
due to frailty or associated comorbidities (gait speed 6s [9/11], grip strength 18kg
[7/11], and cognitive dysfunction [5/11; deﬁned as a score < 4 on the Mini-Cognitive
Assessment for Dementia]). Clinical procedural success was achieved in 9/11 and
partial resheathing/repositioning was successfully performed in 4 patients; no valves
required full retrieval. At 1 year, follow-up was 100% (11/11 patients). There were no
new VARC1 Safety Composite events, bleeding events, or new pacemaker implan-
tation between 30 days and 1 year. The safety composite remained 3/11 (2 patients
with non-valve-related disabling bleeding, 1 with major ischemic stroke and vascular
complication). Conduction disturbance requiring new permanent pacemaker implan-
tation remained at 4 patients; only 2 patients were pacemaker dependent at 1 year.
NYHA class was signiﬁcantly (P¼0.004) improved at 1 year with 5 (46%) patients in
Class I, and 6 (55%) in Class II. Signiﬁcant improvements in mean aortic gradient and
aortic valve area were sustained at 1 year (mean gradient 15.44.6mmHg; mean area
1.50.2cm2; P< 0.001 vs baseline for each). Core laboratory adjudicated paravalvular
aortic regurgitation was trace/trivial in 1 patient, mild in 1 patient, and absent in 8
patients at 1 year.
Conclusions: One-year feasibility results suggest that the Lotus Valve can be posi-
tioned accurately and successfully with virtually no aortic regurgitation and low
clinical event rates. Two-year outcomes from REPRISE I will be presented for the ﬁrst
time at TCT 2014.
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Background: The number of Transcatheter Aortic Valve Replacement (TAVR)
programs has increase in the US. However, the number of referrals to TAVR centers
for evaluation remains uncertain. We sought to describe the temporal changes of
treatment allocation after FDA approval of currently available transcatheter aortic
valves.
Methods: We retrospectively analyzed all patients who were referred to our center
between January 1, 2010, and July 31, 2013. The number of referrals were grouped
and analyzed by year with three distinct landmark time points. These landmark
points represent the approval of the two currently available transcatheter heart
valves.
Results: Following initial screening of 1051 patients, 18% (n¼192) patients under-
went TAVR, 34% (n¼357) balloon aortic valvuloplasty (BAV), 8% (n¼84) surgical
replacement (SAVR) and 40% (n¼418) medical therapy. Mean time from last
screening to TAVR was 26  47 days, and mean time from last screening to SAVR
was 10  15 days. As shown in Figure 1 the number of patients receiving TAVR and
SAVR has increased overtime in contrast to the number of patients treated with BAV
and medical therapy.lvular disease - Aortic: TAVR B213
